Dehydration is one of the warnings printed on the Ozempic label, and it is easy to misread. The label does not say the drug pulls water out of the body. It says the stomach side effects can.
This page covers how the labels frame the risk, how often it reached the kidneys in trials, and what guidance says about fluids.
What the labels say
The Ozempic label’s warning is headed “Acute Kidney Injury Due to Volume Depletion” [1]. It reports postmarketing cases of kidney injury, “in some cases requiring hemodialysis.”
It then names the cause. “The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.”
Prescribers are told to check kidney function in people with those symptoms. The label adds “especially during dosage initiation and escalation.” The Wegovy [2] and Zepbound [3] labels carry the same warning.
The patient section is plainer. “It is important for you to drink fluids to help reduce your chance of dehydration.” It asks you to report nausea, vomiting or diarrhea “that does not go away.”
Older adults and people with kidney disease carry more of this risk. That is covered in GLP-1 medications for seniors.
How common the fluid-losing side effects are
The Wegovy label reports adverse reactions from its weight trials, with 2,116 adults on 2.4 mg and 1,261 on placebo [2].
| Side effect | Wegovy 2.4 mg | Placebo (Wegovy trials) | Zepbound 15 mg | Placebo (Zepbound trials) |
|---|---|---|---|---|
| Nausea | 44% | 16% | 28% | 8% |
| Diarrhea | 30% | 16% | 23% | 8% |
| Vomiting | 24% | 6% | 13% | 2% |
The Zepbound figures come from two pooled weight trials, with 941 adults on 15 mg and 958 on placebo [3]. The two drugs were not compared head to head, so the columns should not be ranked against each other.
Nausea on its own is covered in Ozempic nausea, and loose stools in tirzepatide diarrhea.
How often it reached the kidneys
7 vs 4
Adults with kidney injury in the Wegovy weight trials, drug versus placebo
Wegovy label
0.4 vs 0.2
Kidney injury cases per 100 patient-years, Wegovy versus placebo
Wegovy label
0.5% vs 0.2%
Kidney injury in two pooled Zepbound trials, drug versus placebo
Zepbound label
The Wegovy label says some of its cases “occurred in association with gastrointestinal adverse reactions or dehydration” [2]. Two more trial patients had kidney injury with dehydration in other studies.
It adds that the risk was higher in people with prior kidney impairment. It also “occurred more frequently during dose titration.”
The Zepbound label notes that low blood pressure “also occurred in association with gastrointestinal adverse events and dehydration” [3]. In its table, hypotension affected 2% on 15 mg and 0% on placebo.
What larger analyses found
A 2026 network meta-analysis pooled 67 randomized trials with 199,877 participants [6]. It compared kidney injury across GLP-1 drugs and SGLT2 inhibitors, drug by drug and dose by dose.
Only high-dose tirzepatide, 10 to 15 mg a week, carried a significantly higher risk than controls. The absolute risk difference was 0.28%, a number needed to harm of 357. No semaglutide dose reached significance.
A study of the FDA’s adverse event reports pointed the other way [7]. Kidney injury appeared in 1.07% of semaglutide reports and 0.47% of tirzepatide reports.
That is a count of reports, not of patients at risk. The authors say “causality cannot be confirmed” and warn of reporting bias. The two studies used different methods and should not be read as settling which drug is riskier.
Do these drugs make you drink less?
There is a plausible second route to low fluids. GLP-1 drugs cut appetite, and some evidence suggests they cut drinking too.
A crossover trial gave 20 healthy volunteers dulaglutide 1.5 mg, a different GLP-1 drug, or placebo for three weeks each [5]. At the end of each period, they drank water freely over an 8-hour visit.
Median fluid intake was 1,300 mL on dulaglutide and 1,600 mL on placebo (p = 0.06). Median 24-hour urine output was 1,250 mL against 1,680 mL (p = 0.04).
Thirst ratings did not differ, and blood sodium was 140 mmol/L on both. So people drank less without feeling drier. The study was small, in young healthy adults, and did not test semaglutide.
What guidance says about fluids
The 2025 joint advisory on nutrition during GLP-1 treatment addresses this directly [4]. “Dehydration from severe nausea, vomiting, or diarrhea can cause acute kidney injury,” it says, “as well as heart palpitations.”
It concludes that “efforts should be made to prevent dehydration.” People with or at risk of kidney disease should be counseled on how, and have their kidney function monitored.
Its habits table lists “Ensure adequate fluids” next to regular, small meals. For nausea, it suggests small meals every 3 to 4 hours “while drinking adequate fluids.” It gives no number of glasses.
A multidisciplinary consensus on GI side effects is more specific [8]. For vomiting, it says to “be particularly careful with hydration”, and adds that intravenous fluids are rarely needed.
For diarrhea, it lists “generous hydration, for example with water, lemon and a teaspoon of bicarbonate.” It also says to “avoid isotonic drinks intended to be used in the context of sport activities.”
When dehydration affects other medicines
Less fluid can raise blood levels of drugs cleared by the kidneys. A 2025 case series described three patients on stable lithium who started semaglutide [9].
In two, lithium rose to toxic levels. In the third, a pre-emptive dose cut limited the rise. The authors list dehydration from eating less, vomiting or diarrhea among the possible causes.
Three cases cannot establish a rate. They are a reason to tell the prescriber about any narrow-margin drug you take, not a finding about semaglutide in general.
What the evidence does not tell you
No label, advisory or trial gives a daily fluid target for people on semaglutide. The guidance says “adequate” and leaves the amount to the clinician.
No trial has tested electrolyte drinks, oral rehydration solutions or a set water intake on these drugs. The dulaglutide trial is the only one found that measured drinking directly.
The practical signal from the labels is timing. The risk is highest when starting or raising the dose, and when vomiting or diarrhea will not stop. That is when to call your prescriber. This page is general information, not medical advice. The full side-effect picture is in semaglutide side effects.